According to the aforementioned knowledge, we conducted this study which aimed at evaluating the efficacy and safety of metformin versus empagliflozin, a SGLT2 inhibitor, on CKD progression with exploring proposed mechanistic intermediates in clinical settings. The gene discussed is SLC5A2; the disease is chronic kidney disease.